Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Ebglyss FDA approval intensifies competition in atopic dermatitis market, says GlobalData

Eli Lilly‘s Ebglyss (lebrikizumab) has recently received approval in the US, adding a new competitor to the atopic dermatitis (AD) market alongside therapies like tralokinumab and dupilumab. Although there are current treatment options ranging from topical therapies to systemic treatments  there is a significant unmet need remains for safer and more effective long-term AD therapies, […]
Read more

Non-opioid medications for addiction treatment remain key unmet need in OUD market in 8MM, reveals GlobalData

Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. In August 2024, 110 high-prescribing psychiatrists, addiction specialists, neurologists, and primary care physicians from eight major markets (8MM*) were surveyed by GlobalData on the key unmet […]
Read more

ARS Pharmaceuticals’ Neffy poised to disrupt epinephrine market as first needle-free nasal spray, says GlobalData

ARS Pharmaceuticals’ Neffy, the first needle-free epinephrine nasal spray, is poised to significantly impact the treatment of life-threatening allergic reactions like anaphylaxis following FDA approval in August 2024. With ease of use paired with a strong patient-assistance program, Neffy is set to disrupt the epinephrine market, according to GlobalData, a leading data and analytics company. […]
Read more

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market share following FDA approval, says GlobalData

Following the Food and Drug Administration (FDA) approval of Sanofi/Regeneron’s Dupixent (Dupilumab) on 27 September 2024: Asiyah Nawab, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent, a monoclonal antibody (mAb) targeting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, has been approved by the FDA as the first biologic for uncontrolled […]
Read more

China’s surge in antibody-drug conjugates positions it as key oncology market, says GlobalData

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China’s burgeoning oncology sector. With a little over 100 ADC candidates in various stages of development, Chinese companies lead the Asia-Pacific (APAC) region. As cancer remains a significant health challenge, strategic collaborations with major pharmaceutical companies are essential for advancing research and enhancing […]
Read more

GlobalData poll reveals microbiome’s essential role in health

Healthcare professionals widely recognize the microbiome’s vital contributions to digestion, immune function, and overall well-being. The majority of surveyed respondents view a balanced microbiome as essential to sustain health and prevent various diseases, underscoring its crucial role of in maintaining human health, according to a recent poll conducted by GlobalData, a leading data and analytics […]
Read more

AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake, says GlobalData

The US Food and Drug Administration (FDA) has approved the first self-administered seasonal influenza vaccine – AstraZeneca’s FluMist. FluMist has been available in the US since 2003, but beginning next year, the nasal spray vaccine will also be available for self-administration. This approval increases the accessibility of seasonal influenza vaccines, and has the potential to […]
Read more

mRNA vaccines lead next-generation efforts to combat H5N1 amid global outbreaks, says GlobalData

The H5N1 virus, known for its 50% human case fatality rate, has persisted globally for over two decades, causing thousands of infections. The recent outbreaks, including those affecting US dairy cows, have accelerated the development of next-generation vaccines, with mRNA vaccines stepping into the spotlight, aiming to replicate the success achieved during the COVID-19 pandemic, […]
Read more

Unmet need for prophylactic and therapeutic HSV vaccines remains high as genital herpes prevalence rises, says GlobalData

GSK has recently announced its decision to halt development of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, which was under investigation for genital herpes, after a Phase I/II clinical trial failed to meet its primary efficacy goals. The vaccine was not associated with any safety concerns in the trial. However, owing to the […]
Read more

Atopic Dermatitis: A hotspot for innovation and investment opportunities, says GlobalData

Atopic dermatitis (AD) is emerging as a dynamic field ripe with innovation and investment opportunities. With the market projected to reach $16.7 billion by 2030 across the seven major markets (7MM*), driven by rising prevalence and advancements in treatment, pharmaceutical companies are increasingly focusing on novel therapies. This sector promises substantial growth as new treatments […]
Read more

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 billion in sales by 2030, forecasts GlobalData

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. Bayer’s Xofigo (radium-223 dichloride) demonstrated the proof-of-concept with its FDA approval for castration-resistant prostate cancer (CRPC). Interest in RLTs has since peaked, with Novartis acquiring developer Advanced Accelerator Applications and the highly effective Pluvicto (lutetium [177Lu] vipivotide tetraxetan), targeting prostate-specific […]
Read more

Takeda and Astellas key firms in advancing early gene therapy research in Japan, reveals GlobalData

The gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. In advancing early gene therapy research in Japan, Takeda and Astellas currently stand as […]
Read more

World Sepsis Day 2024: Improved clinical trial design and targeted therapies remain key unmet needs, says GlobalData

World Sepsis Day, which takes place annually on September 13, aims to raise awareness of the devastating condition that claims millions of lives globally each year. Sepsis is a life-threatening and complex disease caused by a dysregulated host immune response to an infection. Currently, there is no drug that specifically targets the underlying pathophysiological processes […]
Read more

Dupert offers new hope for advanced NSCLC patients as China’s first KRAS G12C Inhibitor, says GlobalData

GenFleet Therapeutics and Innovent Biologics have secured approval from China’s National Medical Products Administration (NMPA) for Dupert (fulzerasib), the country’s first KRAS G12C inhibitor for advanced non-small cell lung cancer (NSCLC) in adults who have undergone prior systemic therapy. This breakthrough therapy addresses a challenging mutation, offering a critical new treatment option for patients with […]
Read more

WHO’s mpox response plan provides direction for coordinated response to reduce disease burden, says GlobalData

In response to the mpox outbreak in Africa, the World Health Organization (WHO) has launched an international Strategic Preparedness and Response Plan (SPRP) and hosted a research response conference whereby researchers, public health officials, and stakeholders from affected countries were invited to take the lead in shaping research efforts and aligning them with outbreak response […]
Read more

IASP World Congress highlights need for unified guidelines on opioid use in chronic pain, says GlobalData

At the recently held International Association for the Study of Pain (IASP) World Congress, a presentation during a topical workshop revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management. The inconsistencies raise concerns about the role of CPGs in the overprescription of opioids, potentially exacerbating the risk […]
Read more

Abaloparatide approval to enhance osteoporosis treatment landscape for high-risk patients in UK, says GlobalData

The National Institute for Health and Care Excellence (NICE) approved abaloparatide for treating patients at high risk of fractures in the UK, providing a new and effective treatment option for severe osteoporosis. This approval marks a critical milestone in improving patient outcomes and broadening therapeutic choices in the UK’s osteoporosis market, according to GlobalData, a […]
Read more

Rising ADHD diagnoses in 7MM linked to standardized screening tools and guidelines, says GlobalData

The increase in attention-deficit/hyperactivity disorder (ADHD) diagnoses across the seven major markets (7MM*) is closely tied to the adoption of standardized screening tools and updated clinical guidelines. These developments, particularly in the US, have led to more accurate identification of ADHD cases, especially among adults, helping to address the disorder’s significant socioeconomic and mental health […]
Read more
1 … 14 15 16 17 18 … 108